Last hope before Death of alpha synuclein theory

[Farooqji]

Hope remains that Roche’s prasinezumab can overcome recent string of failures in Parkinson’s disease

Updates on the initiation of the planned Phase IIb trial are expected to read out in the second half of 2021. GlobalData expects that, if approved, prasinezumab could enter the US market by 2028 and that it will see fast initial uptake, generating over $1.5B in peak sales in the US.

clinicaltrialsarena.com/com...

[Parkinsonjisung]

Does anyone know how this differs from the Biogen version?

[redhawk1]

Have now been in phase llb 7 months, infusions every 28 days. In my case PD symptoms have continued to progress. With that said, how is one able to compare rate of progression since you don’t have anything with which to compare. Slowing down progression would certainly be a monumental accomplishment in itself! Phase llB is scheduled to continue for 5 years. So, obviously, Roche is not looking for any “overnight” results. As for me . . . already have a couple CC’s in sight should this trial not prove to be efficacious in some way . . .

[Buckholt in reply to redhawk1]

Good luck to you in the trial. As for results, I think most of us are hoping that one day, a drug will be the “Big Bang” where results are so obvious that it’s not necessary to rely on careful analysis of stats to declare a result!

[sharoncrayn]

2 years ago you wrote the same obituary. A-syn isn't going away as a theory.